MEP1108A - Use of specific dose of fondaparinux sodium for the treatment of acs - Google Patents

Use of specific dose of fondaparinux sodium for the treatment of acs

Info

Publication number
MEP1108A
MEP1108A MEP-11/08A MEP1108A MEP1108A ME P1108 A MEP1108 A ME P1108A ME P1108 A MEP1108 A ME P1108A ME P1108 A MEP1108 A ME P1108A
Authority
ME
Montenegro
Prior art keywords
acs
treatment
sulfo
specific dose
deoxy
Prior art date
Application number
MEP-11/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Anthonie Wilhelmus Arnold Lensing
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8181220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP1108(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MEP1108A publication Critical patent/MEP1108A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
MEP-11/08A 2001-11-13 2002-11-07 Use of specific dose of fondaparinux sodium for the treatment of acs MEP1108A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204323 2001-11-13
PCT/EP2002/012482 WO2003041722A1 (en) 2001-11-13 2002-11-07 Use of specific dose of fondaparinux sodium for the treatment of acs

Publications (1)

Publication Number Publication Date
MEP1108A true MEP1108A (en) 2011-02-10

Family

ID=8181220

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2008-11A ME00229B (me) 2001-11-13 2002-11-07 Primjena specifične doze natrijum fondaparinuksa za liječenje acs
MEP-11/08A MEP1108A (en) 2001-11-13 2002-11-07 Use of specific dose of fondaparinux sodium for the treatment of acs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2008-11A ME00229B (me) 2001-11-13 2002-11-07 Primjena specifične doze natrijum fondaparinuksa za liječenje acs

Country Status (37)

Country Link
US (1) US20040248848A1 (xx)
EP (1) EP1446131B1 (xx)
JP (1) JP4523276B2 (xx)
KR (1) KR20050044318A (xx)
CN (1) CN1602197A (xx)
AP (1) AP1820A (xx)
AR (1) AR037291A1 (xx)
AT (1) ATE361753T1 (xx)
AU (1) AU2002351915B2 (xx)
BR (1) BR0212915A (xx)
CA (1) CA2465776A1 (xx)
CO (1) CO5580790A2 (xx)
CY (1) CY1106765T1 (xx)
DE (1) DE60220084T2 (xx)
DK (1) DK1446131T3 (xx)
EA (1) EA007325B1 (xx)
EC (1) ECSP045041A (xx)
ES (1) ES2287343T3 (xx)
GE (1) GEP20074097B (xx)
HK (1) HK1070561A1 (xx)
HR (1) HRP20040303B1 (xx)
HU (1) HU228959B1 (xx)
IL (2) IL161114A0 (xx)
IS (1) IS2484B (xx)
MA (1) MA27071A1 (xx)
ME (2) ME00229B (xx)
MX (1) MXPA04003045A (xx)
NO (1) NO20041320L (xx)
NZ (1) NZ552129A (xx)
PE (1) PE20030740A1 (xx)
PL (1) PL206008B1 (xx)
PT (1) PT1446131E (xx)
RS (1) RS50906B (xx)
SI (1) SI1446131T1 (xx)
UA (1) UA80399C2 (xx)
WO (1) WO2003041722A1 (xx)
ZA (1) ZA200402464B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075910A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched fondaparinux
BR112017020091A2 (pt) * 2015-03-20 2018-11-06 Aarhus Universitet inibidores de pcsk9 para tratamento de distúrbios do metabolismo de lipoproteínas
US10688249B2 (en) * 2015-06-11 2020-06-23 Virchow Biotech Pvt. Ltd. Multiple dose pharmaceutical compositions containing heparin and/or heparin-like compounds and devices and methods for delivering the same
CN107595769A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种磺达肝癸钠注射液组合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
CA2199642C (en) * 1997-03-10 2001-05-08 Roger Cariou Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
US20040087543A1 (en) * 2002-04-25 2004-05-06 Zachary Shriver Methods and products for mucosal delivery

Also Published As

Publication number Publication date
ZA200402464B (en) 2005-06-29
AU2002351915B2 (en) 2007-11-29
PT1446131E (pt) 2007-08-07
BR0212915A (pt) 2004-10-13
DK1446131T3 (da) 2007-09-10
ME00229B (me) 2011-10-10
HU228959B1 (en) 2013-07-29
HRP20040303A2 (en) 2004-10-31
US20040248848A1 (en) 2004-12-09
MXPA04003045A (es) 2005-06-20
HK1070561A1 (en) 2005-06-24
DE60220084D1 (de) 2007-06-21
MA27071A1 (fr) 2004-12-20
IL161114A0 (en) 2004-08-31
RS26704A (xx) 2007-02-05
KR20050044318A (ko) 2005-05-12
CA2465776A1 (en) 2003-05-22
CO5580790A2 (es) 2005-11-30
AP1820A (en) 2008-01-11
EA007325B1 (ru) 2006-08-25
GEP20074097B (en) 2007-05-10
JP2005509007A (ja) 2005-04-07
EP1446131B1 (en) 2007-05-09
DE60220084T2 (de) 2008-01-10
HUP0401462A2 (en) 2006-02-28
EA200400382A1 (ru) 2004-10-28
IS7199A (is) 2004-03-29
RS50906B (sr) 2010-08-31
CY1106765T1 (el) 2012-05-23
AP2004003014A0 (en) 2004-06-30
NZ552129A (en) 2008-04-30
CN1602197A (zh) 2005-03-30
HUP0401462A3 (en) 2006-04-28
AR037291A1 (es) 2004-11-03
ES2287343T3 (es) 2007-12-16
IS2484B (is) 2008-12-15
UA80399C2 (en) 2007-09-25
ATE361753T1 (de) 2007-06-15
JP4523276B2 (ja) 2010-08-11
EP1446131A1 (en) 2004-08-18
PL369027A1 (en) 2005-04-18
IL161114A (en) 2010-11-30
ECSP045041A (es) 2004-04-28
SI1446131T1 (sl) 2007-10-31
PE20030740A1 (es) 2003-08-28
HRP20040303B1 (en) 2012-02-29
NO20041320L (no) 2004-06-14
WO2003041722A1 (en) 2003-05-22
PL206008B1 (pl) 2010-06-30

Similar Documents

Publication Publication Date Title
ES2190075T3 (es) Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
PT975235E (pt) Formulacoes nutricionais contendo oligossacaridos
MEP10408A (en) Platinum derivative pharmaceutical formulations
AR035711A1 (es) Prodrogas 3' de 2'-desoxi-beta-l-nucleosidos; sus composiciones farmaceuticas; metodo para el tratamiento o profilaxis de una infeccion del virus de la hepatitis b y sus usos para la manufactura de composiciones farmaceuticas
AP2002002674A0 (en) Clear Aqueous Anaesthetic composition.
DK0538011T3 (da) Saltsammensætninger omfattende lipofilt oligosaccharidantibiotikum.
PT1272199E (pt) Terapias de combinacao com actividade de lesao vascular
NO994431L (no) Ny formulering
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
MEP1108A (en) Use of specific dose of fondaparinux sodium for the treatment of acs
ES2176009T3 (es) Utilizacion de cloruro de sodio para reducir la toxicidad gastrointestinal de los derivados de la competencia.
BRPI9916820B8 (pt) composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método
DK0875248T3 (da) Anvendelse af hyaluronsyre og korresponderende salte til fremstilling af en vandig opløsning, der er velegnet som intra-artikulær skyllevæske
ES2197781A1 (es) Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
YU87501A (sh) Farmaceutski kompleksi
EP1411956B8 (en) Use of oversulfated polysaccharides as inhibitors of hiv
JP2005509007A5 (xx)
FR2797446B1 (fr) Derives de phenanthroline-7-ones et leurs applications en therapeutique
JP2005519919A5 (xx)
BR0307196A (pt) Idraparinux (sanorg 34006) para tratamento e profilaxia secundária de eventos tromboembólicos venosos em pacientes com trombose venosa profunda
EA199800848A1 (ru) Гиполипидемическое и антиатеросклеротическое средство
EP1547603A3 (en) Compositions and methods for use in targeting vascular destruction
IT1190961B (it) Derivati dell'acido lattobionico,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono